Entrada Therapeutics, Inc.

TRDA • Biotechnology

$4.99

— 0.00 (0.00%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$187.04M

Growth

—

Cash Flow

1/5

Trend

Volatile

Evidence

Manageable debt level · 0.17Healthy liquidity · 12.53Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:34 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$4.99

Change0.00%

Shares Out42.22M

Market Cap$187.04M

Enterprise Value$12.58M

52W Range4.93 - 16.45

Beta-0.26

P/E-1.13

P/S39.92

P/B0.80

P/FCF-1.39

EV/Sales2.68

Price$4.99

Change0.00%

Shares Out42.22M

Market Cap$187.04M

Enterprise Value$12.58M

52W Range4.93 - 16.45

Beta-0.26

P/E-1.13

P/S39.92

P/B0.80

P/FCF-1.39

EV/Sales2.68

EV/EBITDA-0.07

EV/FCF-0.09

Earnings Yield-88.63%

FCF Yield-71.83%

Dividend Yield0.00%

Gross Margin83.89%

Oper. Margin-6.14%

Profit Margin-5.65%

Debt/Eq0.17

Current Ratio12.53

Quick Ratio12.53

Target$14.00

Target Upside180.56%

Target Median$14.00

Target Range11.00 - 17.00

Volume3.69K

Avg Volume453.88K

EPS Surprise0.11

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

56/100

Why this score▼

Manageable debt level · 0.17Healthy liquidity · 12.53Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

TRDA

Analyst sentiment

Based on 6 analyst votes · 2026-10-19

83/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$10.00

Mean

$13.50

Median

$13.50

High

$17.00

Company Overview

IPO: 10/29/2021

Industry: Biotechnology

P/B i: 0.80

Debt / Equity i: 0.17

Operating Margin: -613.66%

Net Margin: -565.48%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.17

Current Ratio: 12.53

Quick Ratio: 12.53

Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected

PARMAR KUSH

Transaction: 07/31/2026

SELL

Change

-1,718

Price

$6.85

Filing

08/03/2026

Type

SELL

5AM Ventures V, L.P.

Transaction: 07/31/2026

SELL

Change

-1,718

Price

$6.85

Filing

08/03/2026

Type

SELL

PARMAR KUSH

Transaction: 07/30/2026

SELL

Change

-114,756

Price

$6.93

Filing

08/03/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
PARMAR KUSH	SELL	-1,718	$6.85	07/31/2026	08/03/2026
5AM Ventures V, L.P.	SELL	-1,718	$6.85	07/31/2026	08/03/2026
PARMAR KUSH	SELL	-114,756	$6.93	07/30/2026	08/03/2026
5AM Ventures V, L.P.	SELL	-114,756	$6.93	07/30/2026	08/03/2026
Zeiher Bernhardt G	BUY	+19,000	$5.97	06/10/2026	06/12/2026
Thistle Mary	BUY	+19,000	$5.97	06/10/2026	06/12/2026
Radhakrishnan Maha	BUY	+19,000	$5.97	06/10/2026	06/12/2026
Chapman Gina	BUY	+19,000	$5.97	06/10/2026	06/12/2026
KIM PETER S	BUY	+19,000	$5.97	06/10/2026	06/12/2026
PARMAR KUSH	BUY	+19,000	$5.97	06/10/2026	06/12/2026
Zeiher Bernhardt G	BUY	+5,000	$5.86	05/20/2026	05/21/2026
Dowden Nathan J	SELL	-15,000	$1.74	05/04/2026	05/04/2026
Dowden Nathan J	SELL	-15,000	$15.33	05/04/2026	05/04/2026
Sethuraman Natarajan	SELL	-25,907	$15.39	05/04/2026	05/04/2026
WENTWORTH KORY JAMES	SELL	-2,500	$12.95	04/01/2026	04/02/2026
WENTWORTH KORY JAMES	SELL	-11,388	$13.02	03/10/2026	03/11/2026
Dowden Nathan J	SELL	-11,894	$13.05	03/10/2026	03/11/2026
WENTWORTH KORY JAMES	SELL	-5,089	$13.00	03/09/2026	03/11/2026
Dowden Nathan J	SELL	-3,116	$13.02	03/09/2026	03/11/2026
WENTWORTH KORY JAMES	SELL	-7,988	$12.25	03/04/2026	03/06/2026

About the Company

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Source - link

Peers

ACHV ALLO ARCT AVIR CAPR HUMA IMRX SGMT VNDA VYGR

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1.

GlobeNewsWire

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data -- -- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg -- -- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule -- -- ELEVATE-45-201 Cohort 2 enrollment is complete and the Company is on track to report data at the increased dose of 10 mg/kg in the first half of 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. Study participants in Cohort 1 received three doses of 5 mg/kg of ENTR-601-45 or placebo.

GlobeNewsWire

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven by potential validation of its EEV platform. ENTR-601-44's initial dystrophin increase was disappointing, but lower pediatric drug exposure provides a plausible, testable explanation; higher dosing results are expected in Q1 2027. Valuation is anchored by risk-adjusted pipeline estimates and significant cash reserves, with downside to $4–$4.60 if higher dosing fails to deliver.

Seeking Alpha

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved.

GlobeNewsWire

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,583,333 shares of the company's stock, valued at approximately $19,013,000. BlackRock Inc. owned 6.65% of Entrada Therapeutics at

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	-1.06	-0.95	0.11
2026-02-26	-1.32	-0.94	0.38
2025-11-06	-1.04	-1.06	-0.02
2025-08-06	-0.86	-1.04	-0.18
2025-05-08	-0.78	-0.42	0.36
2025-02-27	-0.66	0.03	0.69
2024-11-05	-0.67	-0.35	0.32
2024-08-13	0.14	1.55	1.41
2024-05-07	-0.59	0.68	1.27
2024-03-13	-0.07	-0.29	-0.22
2023-11-07	-0.74	1.02	1.76
2023-08-08	-0.43	-0.78	-0.35